Particular attention should be paid to the fact that several approved disease-modifying therapies (DMTs) that are applied in MS treatment have been found ineffective and even harmful to NMO patients [76], including IFN-β [77], natalizumab [78], fingolimod [79], and alemtuzumab [80]. Here, IFNB1 is linked to neuromyelitis optica.